| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Human Growth Hormone | 30 | 2023 | 642 | 8.680 |
Why?
|
| Pituitary ACTH Hypersecretion | 18 | 2023 | 180 | 7.950 |
Why?
|
| Acromegaly | 22 | 2023 | 315 | 7.540 |
Why?
|
| Pituitary Neoplasms | 24 | 2024 | 1322 | 6.730 |
Why?
|
| Hypopituitarism | 17 | 2023 | 253 | 4.930 |
Why?
|
| Adenoma | 20 | 2024 | 2155 | 4.510 |
Why?
|
| Hyperprolactinemia | 8 | 2022 | 124 | 3.180 |
Why?
|
| Cushing Syndrome | 7 | 2023 | 241 | 3.070 |
Why?
|
| Growth Hormone | 13 | 2023 | 572 | 2.130 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 5 | 2023 | 49 | 2.040 |
Why?
|
| Dwarfism, Pituitary | 3 | 2023 | 39 | 1.940 |
Why?
|
| Pituitary Diseases | 5 | 2023 | 137 | 1.810 |
Why?
|
| Pituitary Gland | 10 | 2023 | 635 | 1.650 |
Why?
|
| Prolactinoma | 3 | 2023 | 114 | 1.650 |
Why?
|
| Diabetes Insipidus | 7 | 2019 | 144 | 1.610 |
Why?
|
| Hydrocortisone | 9 | 2023 | 1840 | 1.550 |
Why?
|
| Adrenal Glands | 4 | 2021 | 557 | 1.500 |
Why?
|
| Bone Density | 12 | 2021 | 3573 | 1.400 |
Why?
|
| Adrenocorticotropic Hormone | 11 | 2023 | 619 | 1.360 |
Why?
|
| Receptors, Somatotropin | 3 | 2020 | 58 | 1.270 |
Why?
|
| Somatostatin | 9 | 2020 | 458 | 1.170 |
Why?
|
| Insulin-Like Growth Factor I | 15 | 2023 | 1939 | 1.160 |
Why?
|
| Craniopharyngioma | 2 | 2021 | 279 | 1.010 |
Why?
|
| Pituitary Hormones | 10 | 2013 | 182 | 0.960 |
Why?
|
| Endocrinology | 4 | 2020 | 443 | 0.910 |
Why?
|
| Peptide Hormones | 4 | 2006 | 132 | 0.850 |
Why?
|
| Dopamine Agonists | 4 | 2022 | 346 | 0.800 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2023 | 733 | 0.790 |
Why?
|
| Saliva | 2 | 2018 | 853 | 0.780 |
Why?
|
| Peptides, Cyclic | 4 | 2020 | 390 | 0.770 |
Why?
|
| Thyrotropin | 3 | 2020 | 834 | 0.760 |
Why?
|
| Adrenal Insufficiency | 5 | 2022 | 194 | 0.760 |
Why?
|
| Bone and Bones | 4 | 2021 | 2587 | 0.750 |
Why?
|
| Hypothalamic Hormones | 8 | 2004 | 145 | 0.690 |
Why?
|
| Enzyme Inhibitors | 2 | 2023 | 3726 | 0.690 |
Why?
|
| Receptors, Somatostatin | 2 | 2020 | 138 | 0.660 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2018 | 309 | 0.660 |
Why?
|
| Melanins | 8 | 2004 | 291 | 0.640 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 2 | 2020 | 64 | 0.630 |
Why?
|
| Mitotane | 4 | 2021 | 20 | 0.630 |
Why?
|
| Frozen Sections | 1 | 2019 | 153 | 0.630 |
Why?
|
| Hormone Replacement Therapy | 5 | 2017 | 756 | 0.620 |
Why?
|
| Brain Injuries | 3 | 2015 | 2053 | 0.620 |
Why?
|
| Spinal Fractures | 2 | 2024 | 710 | 0.600 |
Why?
|
| Neurotransmitter Agents | 3 | 2018 | 661 | 0.600 |
Why?
|
| Octreotide | 2 | 2020 | 156 | 0.600 |
Why?
|
| Leptin | 11 | 2004 | 1599 | 0.590 |
Why?
|
| Antimetabolites | 1 | 2018 | 128 | 0.580 |
Why?
|
| Humans | 132 | 2024 | 767040 | 0.560 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2824 | 0.550 |
Why?
|
| Hypothalamus | 5 | 2013 | 1002 | 0.540 |
Why?
|
| Cytodiagnosis | 1 | 2019 | 450 | 0.500 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.470 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2004 | 856 | 0.460 |
Why?
|
| Radius | 1 | 2017 | 443 | 0.460 |
Why?
|
| Metyrapone | 3 | 2021 | 22 | 0.450 |
Why?
|
| Hormones | 1 | 2018 | 865 | 0.450 |
Why?
|
| Adult | 61 | 2023 | 223317 | 0.450 |
Why?
|
| Ketoconazole | 3 | 2021 | 95 | 0.440 |
Why?
|
| Bromocriptine | 2 | 2023 | 93 | 0.420 |
Why?
|
| Monitoring, Intraoperative | 1 | 2019 | 947 | 0.420 |
Why?
|
| Osteoporotic Fractures | 1 | 2017 | 417 | 0.410 |
Why?
|
| Cranial Irradiation | 1 | 2015 | 393 | 0.400 |
Why?
|
| Endocrine System | 1 | 2013 | 113 | 0.400 |
Why?
|
| Nelson Syndrome | 1 | 2011 | 20 | 0.390 |
Why?
|
| Quality of Life | 9 | 2023 | 13485 | 0.390 |
Why?
|
| Prader-Willi Syndrome | 1 | 2012 | 80 | 0.380 |
Why?
|
| Osteoporosis | 2 | 2017 | 1604 | 0.380 |
Why?
|
| Water-Electrolyte Imbalance | 2 | 2013 | 111 | 0.380 |
Why?
|
| Etomidate | 3 | 2021 | 185 | 0.380 |
Why?
|
| Adrenal Cortex | 1 | 2011 | 134 | 0.370 |
Why?
|
| Neuropeptides | 5 | 2001 | 950 | 0.370 |
Why?
|
| Middle Aged | 53 | 2021 | 223233 | 0.370 |
Why?
|
| Male | 76 | 2022 | 364203 | 0.360 |
Why?
|
| Mifepristone | 3 | 2020 | 151 | 0.360 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2010 | 142 | 0.360 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2011 | 241 | 0.350 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2018 | 1536 | 0.350 |
Why?
|
| Obesity | 13 | 2008 | 13085 | 0.340 |
Why?
|
| Female | 60 | 2024 | 396660 | 0.330 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2008 | 1023 | 0.320 |
Why?
|
| Retrospective Studies | 24 | 2022 | 81659 | 0.320 |
Why?
|
| Tumor Burden | 3 | 2022 | 1903 | 0.320 |
Why?
|
| Adrenoleukodystrophy | 2 | 2022 | 144 | 0.310 |
Why?
|
| Aneurysm | 1 | 2012 | 343 | 0.310 |
Why?
|
| Mortality | 1 | 2020 | 2909 | 0.310 |
Why?
|
| Hormone Antagonists | 2 | 2022 | 108 | 0.300 |
Why?
|
| Thirst | 1 | 2008 | 42 | 0.300 |
Why?
|
| Prolactin | 2 | 2022 | 627 | 0.300 |
Why?
|
| Disease Management | 1 | 2018 | 2531 | 0.290 |
Why?
|
| Carotid Arteries | 1 | 2012 | 934 | 0.280 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2011 | 707 | 0.270 |
Why?
|
| Carcinoma, Medullary | 1 | 2007 | 115 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 9410 | 0.270 |
Why?
|
| Thyroid Gland | 1 | 2013 | 1170 | 0.260 |
Why?
|
| Obesity, Morbid | 3 | 2015 | 1293 | 0.260 |
Why?
|
| Oxytocin | 2 | 2020 | 403 | 0.250 |
Why?
|
| Radiosurgery | 1 | 2015 | 1330 | 0.250 |
Why?
|
| Carotid Artery Diseases | 1 | 2012 | 872 | 0.250 |
Why?
|
| Thinness | 3 | 2004 | 482 | 0.240 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2008 | 2144 | 0.240 |
Why?
|
| Databases, Factual | 4 | 2014 | 8068 | 0.240 |
Why?
|
| Remission Induction | 3 | 2015 | 2408 | 0.240 |
Why?
|
| Neuropeptide Y | 4 | 2001 | 194 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 6513 | 0.230 |
Why?
|
| Aged | 29 | 2020 | 171319 | 0.220 |
Why?
|
| Dizziness | 1 | 2007 | 269 | 0.220 |
Why?
|
| Wrestling | 1 | 2003 | 19 | 0.220 |
Why?
|
| Hyperaldosteronism | 1 | 2007 | 252 | 0.220 |
Why?
|
| Adrenalectomy | 3 | 2011 | 347 | 0.220 |
Why?
|
| Societies, Medical | 2 | 2016 | 3964 | 0.220 |
Why?
|
| Body Mass Index | 10 | 2020 | 13048 | 0.220 |
Why?
|
| Hypothyroidism | 2 | 2015 | 667 | 0.220 |
Why?
|
| Anorexia | 1 | 2004 | 153 | 0.220 |
Why?
|
| Lumbar Vertebrae | 1 | 2013 | 1885 | 0.220 |
Why?
|
| Hypothalamic Area, Lateral | 2 | 2001 | 108 | 0.210 |
Why?
|
| Arginine | 2 | 2020 | 931 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2021 | 36582 | 0.200 |
Why?
|
| Thyroid Neoplasms | 2 | 2007 | 2355 | 0.200 |
Why?
|
| Ghrelin | 4 | 2006 | 251 | 0.200 |
Why?
|
| ROC Curve | 2 | 2020 | 3618 | 0.200 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2002 | 101 | 0.200 |
Why?
|
| Internationality | 2 | 2021 | 1006 | 0.190 |
Why?
|
| Young Adult | 15 | 2020 | 59980 | 0.190 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12536 | 0.190 |
Why?
|
| Glucose Tolerance Test | 5 | 2020 | 1181 | 0.190 |
Why?
|
| Diastole | 1 | 2004 | 784 | 0.190 |
Why?
|
| Prognosis | 9 | 2020 | 29963 | 0.180 |
Why?
|
| Disease Progression | 1 | 2018 | 13646 | 0.180 |
Why?
|
| Iopamidol | 1 | 2001 | 188 | 0.180 |
Why?
|
| Postoperative Period | 4 | 2020 | 1824 | 0.180 |
Why?
|
| Diagnosis, Differential | 4 | 2023 | 12986 | 0.180 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2020 | 20 | 0.170 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2020 | 43 | 0.170 |
Why?
|
| Chemokine CCL2 | 1 | 2002 | 605 | 0.170 |
Why?
|
| Melanocyte-Stimulating Hormones | 1 | 1999 | 25 | 0.170 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2001 | 128 | 0.170 |
Why?
|
| Treatment Outcome | 13 | 2020 | 65295 | 0.170 |
Why?
|
| Eating | 4 | 2001 | 1541 | 0.170 |
Why?
|
| Fasting | 2 | 2003 | 1607 | 0.170 |
Why?
|
| Water-Electrolyte Balance | 2 | 2013 | 326 | 0.170 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2012 | 187 | 0.160 |
Why?
|
| Carcinoma, Papillary | 1 | 2004 | 791 | 0.160 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2000 | 88 | 0.160 |
Why?
|
| Cold Temperature | 1 | 2003 | 793 | 0.160 |
Why?
|
| Fractures, Bone | 3 | 2017 | 2062 | 0.160 |
Why?
|
| Sarcoidosis | 1 | 2004 | 535 | 0.160 |
Why?
|
| Premenopause | 2 | 2021 | 1039 | 0.160 |
Why?
|
| Histiocytosis | 1 | 1998 | 40 | 0.160 |
Why?
|
| Neurotensin | 1 | 1998 | 59 | 0.150 |
Why?
|
| Intraoperative Period | 1 | 2019 | 512 | 0.150 |
Why?
|
| Vasopressins | 1 | 2020 | 358 | 0.150 |
Why?
|
| alpha-MSH | 1 | 1998 | 71 | 0.150 |
Why?
|
| Bone Density Conservation Agents | 1 | 2005 | 797 | 0.150 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2000 | 161 | 0.150 |
Why?
|
| Absorptiometry, Photon | 2 | 2017 | 1757 | 0.150 |
Why?
|
| Off-Label Use | 1 | 2020 | 185 | 0.150 |
Why?
|
| Glucagon | 2 | 2016 | 534 | 0.150 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2020 | 164 | 0.150 |
Why?
|
| Aorta | 1 | 2005 | 2045 | 0.150 |
Why?
|
| Hyperparathyroidism | 1 | 1999 | 339 | 0.150 |
Why?
|
| RNA, Messenger | 7 | 2013 | 12793 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1998 | 243 | 0.150 |
Why?
|
| Diphtheria Toxin | 1 | 1998 | 253 | 0.150 |
Why?
|
| Homeostasis | 4 | 2008 | 3345 | 0.140 |
Why?
|
| Pelvic Bones | 1 | 2020 | 274 | 0.140 |
Why?
|
| Museums | 1 | 1997 | 23 | 0.140 |
Why?
|
| Parathyroidectomy | 1 | 1999 | 244 | 0.140 |
Why?
|
| Circadian Rhythm | 3 | 2018 | 2591 | 0.140 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 1998 | 271 | 0.140 |
Why?
|
| Age of Onset | 3 | 2016 | 3344 | 0.140 |
Why?
|
| Radiography | 3 | 2013 | 6975 | 0.140 |
Why?
|
| Protein Precursors | 1 | 2001 | 1134 | 0.140 |
Why?
|
| Estradiol | 1 | 2004 | 1951 | 0.140 |
Why?
|
| Appetite | 1 | 1998 | 247 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2003 | 1883 | 0.130 |
Why?
|
| Endocrine System Diseases | 1 | 1998 | 250 | 0.130 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2016 | 43 | 0.130 |
Why?
|
| Cardiovascular System | 1 | 2004 | 839 | 0.130 |
Why?
|
| Proteins | 6 | 1998 | 6001 | 0.130 |
Why?
|
| Brain Hemorrhage, Traumatic | 1 | 2015 | 18 | 0.130 |
Why?
|
| Insulin | 5 | 2020 | 6602 | 0.130 |
Why?
|
| Insulin Infusion Systems | 1 | 1997 | 221 | 0.120 |
Why?
|
| Goals | 1 | 2021 | 717 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 1364 | 0.120 |
Why?
|
| Gastric Bypass | 1 | 2003 | 820 | 0.120 |
Why?
|
| Imidazoles | 1 | 2021 | 1169 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2020 | 10393 | 0.120 |
Why?
|
| Ventricular Function, Left | 2 | 2005 | 3934 | 0.120 |
Why?
|
| Animals | 21 | 2018 | 168965 | 0.120 |
Why?
|
| Age Factors | 6 | 2020 | 18401 | 0.110 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2016 | 468 | 0.110 |
Why?
|
| Neoplasms | 1 | 2023 | 22350 | 0.110 |
Why?
|
| Consensus | 2 | 2022 | 3207 | 0.110 |
Why?
|
| Logistic Models | 2 | 2020 | 13284 | 0.110 |
Why?
|
| Hyperthyroidism | 1 | 2016 | 292 | 0.110 |
Why?
|
| Child | 8 | 2023 | 80771 | 0.110 |
Why?
|
| Nocturnal Enuresis | 1 | 2013 | 12 | 0.110 |
Why?
|
| Risk Factors | 9 | 2020 | 74886 | 0.110 |
Why?
|
| Polyuria | 1 | 2013 | 37 | 0.110 |
Why?
|
| Recombinant Proteins | 2 | 2014 | 6507 | 0.110 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 411 | 0.110 |
Why?
|
| Metabolome | 1 | 2020 | 1008 | 0.100 |
Why?
|
| Petrosal Sinus Sampling | 1 | 2012 | 22 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 2201 | 0.100 |
Why?
|
| Adipose Tissue, Brown | 1 | 1998 | 776 | 0.100 |
Why?
|
| Adipose Tissue | 2 | 2004 | 3324 | 0.100 |
Why?
|
| Cross-Sectional Studies | 10 | 2022 | 26325 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 951 | 0.100 |
Why?
|
| Time Factors | 6 | 2020 | 40154 | 0.100 |
Why?
|
| Cerebellum | 2 | 1998 | 1521 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2001 | 11923 | 0.100 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2012 | 85 | 0.100 |
Why?
|
| Case-Control Studies | 6 | 2020 | 22254 | 0.100 |
Why?
|
| Weight Loss | 1 | 2003 | 2716 | 0.100 |
Why?
|
| Bayes Theorem | 1 | 2020 | 2353 | 0.100 |
Why?
|
| Endpoint Determination | 2 | 2019 | 592 | 0.100 |
Why?
|
| Blood Pressure | 2 | 2005 | 8531 | 0.090 |
Why?
|
| Glucose | 1 | 2003 | 4341 | 0.090 |
Why?
|
| Impulsive Behavior | 1 | 2014 | 345 | 0.090 |
Why?
|
| Femur Neck | 1 | 2013 | 318 | 0.090 |
Why?
|
| Stimulation, Chemical | 1 | 2011 | 305 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 1998 | 1407 | 0.090 |
Why?
|
| Receptors, Pituitary Hormone | 2 | 2001 | 29 | 0.090 |
Why?
|
| Lipids | 2 | 2020 | 3322 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 630 | 0.090 |
Why?
|
| Adrenal Gland Diseases | 1 | 2011 | 141 | 0.090 |
Why?
|
| Adolescent | 10 | 2019 | 89046 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 384 | 0.090 |
Why?
|
| Review Literature as Topic | 1 | 2012 | 297 | 0.090 |
Why?
|
| Hypothalamo-Hypophyseal System | 3 | 2019 | 703 | 0.090 |
Why?
|
| Mice, Mutant Strains | 2 | 2004 | 1751 | 0.090 |
Why?
|
| Dizocilpine Maleate | 3 | 1999 | 171 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8535 | 0.080 |
Why?
|
| Accidents, Traffic | 1 | 2015 | 818 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 1788 | 0.080 |
Why?
|
| Diazepam | 3 | 1999 | 215 | 0.080 |
Why?
|
| Cause of Death | 1 | 2020 | 3717 | 0.080 |
Why?
|
| Hypogonadism | 1 | 2015 | 805 | 0.080 |
Why?
|
| Energy Metabolism | 2 | 1999 | 2906 | 0.080 |
Why?
|
| Pyridines | 1 | 2021 | 2890 | 0.080 |
Why?
|
| Muscle Weakness | 1 | 2011 | 412 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 13650 | 0.080 |
Why?
|
| GABA Modulators | 2 | 1999 | 108 | 0.080 |
Why?
|
| Propranolol | 3 | 1999 | 493 | 0.080 |
Why?
|
| Hyperplasia | 1 | 2011 | 1150 | 0.080 |
Why?
|
| Nose | 1 | 2012 | 522 | 0.080 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 39317 | 0.080 |
Why?
|
| Insulin Resistance | 2 | 2001 | 3986 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2004 | 6550 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2020 | 4522 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 3552 | 0.070 |
Why?
|
| Contrast Media | 1 | 2001 | 5329 | 0.070 |
Why?
|
| Gestational Age | 1 | 2016 | 3618 | 0.070 |
Why?
|
| Hippocampus | 2 | 1999 | 3777 | 0.070 |
Why?
|
| In Situ Hybridization | 2 | 2003 | 1892 | 0.070 |
Why?
|
| Receptors, Ghrelin | 1 | 2006 | 20 | 0.070 |
Why?
|
| Blood Glucose | 3 | 2018 | 6421 | 0.070 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 1999 | 451 | 0.070 |
Why?
|
| Elasticity | 2 | 2005 | 654 | 0.070 |
Why?
|
| Heart Failure, Systolic | 1 | 2008 | 134 | 0.070 |
Why?
|
| Rats, Wistar | 3 | 1999 | 1885 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 1998 | 5141 | 0.060 |
Why?
|
| Rats | 7 | 2003 | 23713 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 5519 | 0.060 |
Why?
|
| Calcitonin | 1 | 2007 | 328 | 0.060 |
Why?
|
| Appetite Regulation | 1 | 2006 | 84 | 0.060 |
Why?
|
| Mice | 10 | 2016 | 81912 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 1998 | 4401 | 0.060 |
Why?
|
| Bariatric Surgery | 1 | 2015 | 998 | 0.060 |
Why?
|
| Pediatrics | 1 | 2020 | 3621 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 11063 | 0.060 |
Why?
|
| Neurosurgical Procedures | 2 | 2016 | 2075 | 0.060 |
Why?
|
| Quinazolines | 1 | 2012 | 1369 | 0.060 |
Why?
|
| Cardiac Output | 1 | 2008 | 837 | 0.060 |
Why?
|
| Liver Neoplasms | 1 | 2001 | 4357 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 15424 | 0.060 |
Why?
|
| Vascular Resistance | 1 | 2008 | 939 | 0.060 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2006 | 239 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2018 | 54886 | 0.060 |
Why?
|
| Mice, Knockout | 4 | 2004 | 14476 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 59548 | 0.060 |
Why?
|
| Gastrointestinal Motility | 1 | 2006 | 235 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 5716 | 0.060 |
Why?
|
| Spine | 1 | 2011 | 1139 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2022 | 26396 | 0.060 |
Why?
|
| Drug Implants | 1 | 2004 | 230 | 0.050 |
Why?
|
| Heart Failure | 1 | 2008 | 11877 | 0.050 |
Why?
|
| Mice, Obese | 1 | 2004 | 417 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2003 | 12158 | 0.050 |
Why?
|
| Body Composition | 2 | 2012 | 2454 | 0.050 |
Why?
|
| Gastric Mucosa | 1 | 2006 | 602 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 14766 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 1999 | 1243 | 0.050 |
Why?
|
| Chemokine CCL4 | 1 | 2002 | 127 | 0.050 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2002 | 122 | 0.050 |
Why?
|
| Recurrence | 1 | 2015 | 8504 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2003 | 8108 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 6 | 2004 | 22361 | 0.050 |
Why?
|
| Delayed-Action Preparations | 2 | 2016 | 965 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 14672 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3112 | 0.050 |
Why?
|
| Sex Factors | 3 | 2014 | 10622 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3234 | 0.050 |
Why?
|
| Seizures | 1 | 2015 | 2996 | 0.050 |
Why?
|
| Aldosterone | 1 | 2007 | 881 | 0.050 |
Why?
|
| Calcium | 2 | 2014 | 5792 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2003 | 527 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 1131 | 0.050 |
Why?
|
| Stroke Volume | 2 | 2008 | 5618 | 0.050 |
Why?
|
| Vitamin D | 2 | 2014 | 3312 | 0.050 |
Why?
|
| Neurons | 1 | 2001 | 9517 | 0.050 |
Why?
|
| Thyroidectomy | 1 | 2007 | 912 | 0.050 |
Why?
|
| Placebos | 1 | 2005 | 1660 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2008 | 1873 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 30238 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3599 | 0.040 |
Why?
|
| Acute Disease | 2 | 2003 | 7236 | 0.040 |
Why?
|
| Brain | 3 | 2003 | 27163 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2011 | 2647 | 0.040 |
Why?
|
| Swimming | 2 | 1998 | 212 | 0.040 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 15645 | 0.040 |
Why?
|
| Cerebral Cortex | 2 | 2015 | 5754 | 0.040 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2020 | 20 | 0.040 |
Why?
|
| Aorta, Abdominal | 1 | 2003 | 627 | 0.040 |
Why?
|
| Hepatic Artery | 1 | 2001 | 233 | 0.040 |
Why?
|
| Species Specificity | 1 | 2004 | 2412 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2004 | 698 | 0.040 |
Why?
|
| Ventricular Function, Right | 1 | 2004 | 629 | 0.040 |
Why?
|
| Arginine Vasopressin | 1 | 2019 | 125 | 0.040 |
Why?
|
| Flumazenil | 1 | 1999 | 84 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2005 | 2105 | 0.040 |
Why?
|
| Japan | 1 | 2003 | 1418 | 0.040 |
Why?
|
| Appetite Stimulants | 1 | 1998 | 14 | 0.040 |
Why?
|
| Finite Element Analysis | 1 | 2021 | 441 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 1999 | 411 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 1998 | 227 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2006 | 1244 | 0.040 |
Why?
|
| Pro-Opiomelanocortin | 1 | 1998 | 139 | 0.040 |
Why?
|
| RNA, Antisense | 1 | 1998 | 136 | 0.040 |
Why?
|
| Chemokines | 1 | 2002 | 963 | 0.040 |
Why?
|
| Triiodothyronine | 1 | 2020 | 493 | 0.040 |
Why?
|
| Appetite Depressants | 1 | 1998 | 108 | 0.040 |
Why?
|
| Therapeutics | 1 | 1998 | 113 | 0.040 |
Why?
|
| Intracranial Aneurysm | 1 | 2008 | 1271 | 0.040 |
Why?
|
| Autoradiography | 1 | 1998 | 725 | 0.040 |
Why?
|
| Neonatal Screening | 1 | 2022 | 620 | 0.040 |
Why?
|
| Penile Erection | 1 | 1998 | 100 | 0.040 |
Why?
|
| Gonadotropins | 1 | 1998 | 241 | 0.040 |
Why?
|
| Immobilization | 1 | 1998 | 229 | 0.040 |
Why?
|
| Radiation | 1 | 1997 | 48 | 0.040 |
Why?
|
| Blotting, Northern | 1 | 1999 | 1550 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 9245 | 0.040 |
Why?
|
| Chromatography, Gel | 1 | 1998 | 634 | 0.040 |
Why?
|
| Thyroid Hormones | 1 | 2020 | 408 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 41718 | 0.030 |
Why?
|
| Glucagon-Like Peptides | 1 | 1998 | 157 | 0.030 |
Why?
|
| Genes, fos | 1 | 1997 | 176 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2021 | 1655 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2003 | 772 | 0.030 |
Why?
|
| Postmenopause | 1 | 2005 | 2518 | 0.030 |
Why?
|
| Aorta, Thoracic | 1 | 2003 | 1110 | 0.030 |
Why?
|
| Thyroxine | 1 | 2020 | 666 | 0.030 |
Why?
|
| Psychopathology | 1 | 2019 | 434 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2020 | 1531 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2004 | 2001 | 0.030 |
Why?
|
| Temperature | 1 | 2003 | 2232 | 0.030 |
Why?
|
| Spinal Cord Diseases | 1 | 2019 | 291 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15824 | 0.030 |
Why?
|
| Glucose Intolerance | 1 | 2020 | 579 | 0.030 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 1998 | 374 | 0.030 |
Why?
|
| Melanoma | 1 | 2014 | 5702 | 0.030 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 724 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 3804 | 0.030 |
Why?
|
| Thyroid Nodule | 1 | 2002 | 765 | 0.030 |
Why?
|
| Pituitary-Adrenal System | 1 | 1998 | 555 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 935 | 0.030 |
Why?
|
| Urban Population | 2 | 1993 | 2044 | 0.030 |
Why?
|
| Equipment Failure | 1 | 1997 | 585 | 0.030 |
Why?
|
| Receptor, Insulin | 1 | 1998 | 839 | 0.030 |
Why?
|
| Hypercalcemia | 1 | 1997 | 424 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2020 | 1000 | 0.030 |
Why?
|
| Kinetics | 2 | 2000 | 6287 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1997 | 582 | 0.030 |
Why?
|
| Ergolines | 1 | 2014 | 55 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2019 | 42606 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1998 | 1419 | 0.030 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1999 | 903 | 0.030 |
Why?
|
| Self Report | 2 | 2016 | 3773 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 1078 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2004 | 3468 | 0.030 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1996 | 488 | 0.030 |
Why?
|
| Hypophysectomy | 1 | 2013 | 114 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2020 | 1319 | 0.030 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 5886 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 2850 | 0.030 |
Why?
|
| Stress, Psychological | 2 | 1999 | 4526 | 0.030 |
Why?
|
| Heart Rate | 1 | 2004 | 4209 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20741 | 0.020 |
Why?
|
| Syndrome | 1 | 1998 | 3271 | 0.020 |
Why?
|
| Testosterone | 2 | 2020 | 2490 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 1998 | 956 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 10748 | 0.020 |
Why?
|
| Down-Regulation | 1 | 1999 | 2931 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 1466 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 14098 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2005 | 12451 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 1895 | 0.020 |
Why?
|
| Phenotype | 2 | 2020 | 16718 | 0.020 |
Why?
|
| Exercise | 1 | 2008 | 5954 | 0.020 |
Why?
|
| Feeding Behavior | 2 | 2000 | 3207 | 0.020 |
Why?
|
| Diabetic Angiopathies | 1 | 1996 | 806 | 0.020 |
Why?
|
| Myocardium | 1 | 2004 | 4765 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2001 | 2887 | 0.020 |
Why?
|
| Prevalence | 3 | 2019 | 15851 | 0.020 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2012 | 362 | 0.020 |
Why?
|
| Metabolomics | 1 | 2020 | 1675 | 0.020 |
Why?
|
| Central Nervous System | 1 | 1997 | 1345 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 12069 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2013 | 748 | 0.020 |
Why?
|
| Heart | 1 | 2003 | 4429 | 0.020 |
Why?
|
| Brain Diseases | 1 | 2019 | 1551 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2015 | 2658 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2020 | 2516 | 0.020 |
Why?
|
| Reference Values | 1 | 2016 | 4918 | 0.020 |
Why?
|
| Patient Preference | 1 | 2016 | 947 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 2204 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2012 | 871 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2002 | 9362 | 0.020 |
Why?
|
| Health Status | 1 | 2020 | 4091 | 0.020 |
Why?
|
| Echocardiography | 1 | 2020 | 5042 | 0.020 |
Why?
|
| Massachusetts | 1 | 2000 | 8890 | 0.020 |
Why?
|
| Communication | 1 | 2020 | 3904 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 10092 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2012 | 1472 | 0.020 |
Why?
|
| Survival Rate | 1 | 2000 | 12823 | 0.020 |
Why?
|
| Weight Gain | 1 | 2015 | 2360 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 1998 | 4045 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 1997 | 0.010 |
Why?
|
| Mutation | 2 | 2020 | 30211 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 3611 | 0.010 |
Why?
|
| Psychometrics | 1 | 2014 | 3060 | 0.010 |
Why?
|
| Smoking | 2 | 1998 | 9081 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 1889 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7435 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1997 | 7611 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6844 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1997 | 3449 | 0.010 |
Why?
|
| Greece | 2 | 1993 | 340 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1998 | 8048 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 2902 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2014 | 8732 | 0.010 |
Why?
|
| United States | 2 | 2020 | 72971 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8736 | 0.010 |
Why?
|
| Microsomes | 1 | 2000 | 252 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 2000 | 245 | 0.010 |
Why?
|
| Receptors, Leptin | 1 | 2001 | 352 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2000 | 386 | 0.010 |
Why?
|
| Hypertension | 2 | 2015 | 8615 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1998 | 220 | 0.010 |
Why?
|
| Food Deprivation | 1 | 1998 | 114 | 0.010 |
Why?
|
| Agouti-Related Protein | 1 | 1998 | 95 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 1989 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 2000 | 697 | 0.010 |
Why?
|
| HIV Wasting Syndrome | 1 | 1997 | 99 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 24299 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2013 | 8628 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 36485 | 0.010 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 1997 | 327 | 0.010 |
Why?
|
| Biological Transport | 1 | 2000 | 2084 | 0.010 |
Why?
|
| Cell Line | 2 | 2000 | 15567 | 0.010 |
Why?
|
| Restraint, Physical | 1 | 1997 | 184 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 1993 | 5363 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 6215 | 0.010 |
Why?
|
| Diphosphonates | 1 | 1997 | 633 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 6106 | 0.010 |
Why?
|
| Organ Specificity | 1 | 1997 | 1966 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1996 | 12250 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1996 | 1055 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1998 | 2668 | 0.010 |
Why?
|
| Energy Intake | 1 | 1998 | 2145 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1997 | 1804 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2000 | 3642 | 0.010 |
Why?
|
| Body Weight | 1 | 2001 | 4627 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 4052 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 12414 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1996 | 1816 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 13411 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 9551 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 17608 | 0.000 |
Why?
|
| Triglycerides | 1 | 1996 | 2444 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 2000 | 3698 | 0.000 |
Why?
|
| Linear Models | 1 | 1998 | 5875 | 0.000 |
Why?
|
| Cholesterol | 1 | 1996 | 2905 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1996 | 6331 | 0.000 |
Why?
|
| Stem Cells | 1 | 1998 | 3535 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 4049 | 0.000 |
Why?
|
| Hypoglycemic Agents | 1 | 1993 | 3108 | 0.000 |
Why?
|